DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy

Phase 3

Completed

Conditions: Tendinopathy

Interventions: Other: Placebo
Drug: secukinumab

First Posted Date: 2022-10-06

Last Posted Date: 2025-01-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 62

Registration Number: NCT05569174

Locations: 🇩🇪
Novartis Investigative Site, Schoenebeck, Germany

Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Drug: Ribociclib

First Posted Date: 2022-10-06

Last Posted Date: 2022-11-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 76

Registration Number: NCT05569187

Locations: 🇧🇷
Novartis Investigative Site, Sao Paulo, SP, Brazil

Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Other: Ofatumumab

First Posted Date: 2022-10-04

Last Posted Date: 2025-01-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 307

Registration Number: NCT05566756

Locations: 🇩🇪
Novartis Investigative Site, Unterhaching, Germany

An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

Phase 2

Completed

Conditions: Resistant Hypertension

Interventions: Biological: Experimental drug
Other: Placebo

First Posted Date: 2022-10-03

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 191

Registration Number: NCT05562934

Locations: 🇺🇸
Pinnacle Research Group Llc, Anniston, Alabama, United States
🇺🇸
Parkway Medical Center, Birmingham, Alabama, United States
🇺🇸
Orange County Research Center, Tustin, California, United States

and more 16 locations

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

Phase 3

Recruiting

Conditions: Asthma

Interventions: Drug: QMF149
Drug: Budesonide

First Posted Date: 2022-09-30

Last Posted Date: 2025-05-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT05562466

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Phase 1

Recruiting

Conditions: Myeloid Diseases

Interventions: Drug: DFV890

First Posted Date: 2022-09-23

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 80

Registration Number: NCT05552469

Locations: 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 8 locations

Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera

Active, not recruiting

Conditions: Polycythemia Vera

Interventions: Other: Ruxolitinib
Other: Hydroxyurea

First Posted Date: 2022-09-21

Last Posted Date: 2025-01-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 242

Registration Number: NCT05548062

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

Phase 1

Recruiting

Conditions: Carcinoma, Renal Cell
Cutaneous Melanoma
Carcinoma, Ovarian Epithelial
Nasopharyngeal Carcinoma
Carcinoma, Thymic
Anal Cancer
Squamous Cell Carcinoma of Head and Neck
Esophagogastric Cancer
Triple Negative Breast Neoplasms
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: KFA115
Drug: pembrolizumab

First Posted Date: 2022-09-19

Last Posted Date: 2025-05-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 180

Registration Number: NCT05544929

Locations: 🇺🇸
Massachusetts General Hospital ., Boston, Massachusetts, United States
🇺🇸
NYU School of Medicine, New York, New York, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 2 locations

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Phase 1

Withdrawn

Conditions: Renal Impairment

Interventions: Drug: TNO155

First Posted Date: 2022-09-15

Last Posted Date: 2024-02-29

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT05541159

Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel

Completed

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Other: Tisagenlecleucel

First Posted Date: 2022-09-15

Last Posted Date: 2022-09-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 169

Registration Number: NCT05541328

Locations: 🇺🇸
Novartis Investigative Site, East Hanover, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy